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lineAbstract A series of azoimine palladium(II) complexes of the general type cis-[PdCl2L] (1–6)
{L = PhN‚NC(COMe)‚NC6H4X, where X = H (L1), CH3 (L2), Cl (L3), Br (L4), naphthyl
(L5) and OMe (L6)} have been prepared by the reaction of cis-[PdCl2(NCPh)2] and the ligands
(L) in acetone at room temperature. These complexes have been characterized by spectroscopic
(IR-, UV–Vis and NMR) and electrochemical techniques. In addition, their biological activity
has been studied via MTT test and by detecting the inhibition of clonal growth in three tumor cell
lines, namely T47D human ductal breast carcinoma, MTLn3 murine mammary adenocarcinoma
and RAW 264.7 murine leukemic monocyte macrophage. All of the tested palladium(II) complexes
showed a noticeable antitumor activity. Complexes 4 and 5 showed a higher cytotoxic activity
against human T47D breast tumor cell line than cisplatin, while comparable activity was observed
against murine mammary MTLn3 adenocarcinoma cell line.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The landmark discovery of cisplatin, cis-[PtCl2(NH3)2], by
Rosenberg et al. (1965) heralded a new area of anticancer drug
research. Cisplatin is one of the most effective chemotherapeu-
tic agents in clinical use for the treatment of a testicular and
ovarian cancer (Rosenberg et al., 1965; Abu-Surrah and
Kettunen, 2006). This anticancer activity stems from the bind-
ing of the cis-Pt(NH3)2 fragment with DNA bases. However,
cisplatin also interacts with non-cancer cells, through bond for-
mation with –SH group, resulting in nephrotoxicity. Research-
ers focused on how to reduce the toxicity of cis-platinum
complexes (nausea, ear damage, vomiting, loss of sensation in
hands, and kidney toxicity) and increase their spectrum activity
S1504 M. Al-Noaimi et al.against some of the commonest tumors (e.g. colon and breast)
to improve the efﬁciency as antitumor drug (Reedjik, 1996;
Reedijk, 1987). This has aroused interests in the design of pal-
ladium(II) complexes of improved activity and lower toxicity.
The signiﬁcant similarity between the coordination chemis-
try of palladium(II) and platinum(II) compounds has encour-
aged researchers to use Pd(II) complexes as antitumor drugs
(Abu-Surrah etal., 2008). Numerous palladium complexes with
promising activity against tumor cell lines have been synthe-
sized (Graham and Williams, 1979; Barton, 1986). Comparing
to cis-platin which is a commonly used drug, palladium com-
plexes are hydrolyzed 105 times faster than their corresponding
platinum analogues which make them unable to reach their
pharmacological targets (Abu-Surrah et al., 2008). For exam-
ple, cis-[PdCl2(NH3)2] and cis-[PdCl2(DACH)] (DACH:
(1R,2R)-(–)-1,2-diaminocyclohexane (Butour etal., 1997; Zhao
et al., 1999) do not show antitumor activity. It is well known
that the former undergoes an inactive trans isomer. In addi-
tion, both compounds hydrolyze very fast and interact
in vivo with a lot of proteins molecules which prevent them
to reach the DNA target (Butour et al., 1997; Zhao et al.,
1999). Mono-dentate ligands can bind in both cis- and trans-
arrangements around a metal center (Abu-Surrah et al.,
2002). To prevent hydrolysis and any possible cis–trans isom-
erism for palladium complexes (Mansuri-Torshizi et al.,
1992; Abu-Surrah et al., 2010), palladium ion should be stabi-
lized by strongly and non-labile bidentate ligands (Abu-Surrah
et al., 2008).
Transition-metal complexes incorporating azo ligands such
as arylazooximes (Casas et al., 2008), arylazophenols (Basuli et
al., 1999) and arylazoimines (Mishra et al., 1998) had drawn
much attention. These ligands have low-lying p* orbitals and
can stabilize the low valence metal redox state such as Pd(II)
by promoting metal-to-ligand charge-transfer (MLCT) transi-
tions (Kaim, 2001). Recently, a new class of azoimine ligands
of the general type PhN= NC(R) = NPh has been prepared
by us. Previously, we synthesized a family of complexes
of the general type trans-[RuII(Y)LCl2] {L = C6H5N‚
NC(COCH3)‚NAr, Y = a-diamines} (Al-Noaimi et al.,
2007; Al-Noaimi et al., 2008; Al-Noaimi et al., 2010) to study
the effect of the substituents of the aromatic ring (Ar) on the
electronic properties of the ruthenium center. In this study,
we extend our work to prepare a new family of palladium(II)
complexes of the general formula, cis-[PdCl2L] (1–6) {L =
PhN‚NC(COMe)‚NC6H4X, where X = H (L1), CH3
(L2), Cl (L3), Br (L4), naphthyl (L5) and OMe (L6)}. In addi-
tion, the in vitro cytotoxic (IC50) and anti-proliferation poten-
tial of the complexes (2–5) against human T47D breast tumor,
murine mammary MTLn3 adenocarcinoma and murine RAW
264.7 leukemia cell lines have also been evaluated.
2. Experimental
2.1. Chemistry
2.1.1. Materials and physical measurements
The reagents: azoimine ligands (L1–L6) were prepared accord-
ing to reported procedures (Al-Noaimi et al., 2008). Tetrabu-
tylammonium hexaﬂuorophosphate (TBAHF), purchased
from Aldrich, was recrystallized twice from 1:1 ethanol/watersolution and then vacuum dried at 110 C. cis-[PdCl2(PhCN)2]
was prepared following the procedure (Evans et al., 1968).
2.1.2. Instrumentation
Micro-analyses (C, H, N) were performed using an elemental
analyzer EURO VECTOR model EA3000. IR spectra were
obtained by FT-IR JASCO model 420. Electronic spectra were
recorded on a Shimadzu 240-UV–visible spectrophotometer.
The 1H spectra were measured on a Bruker-Avance 400
MHz spectrometer at 400 MHz using TMS as an internal stan-
dard. Electrochemical measurements were performed in 99.8%
anhydrous acetonitrile (Aldrich, HPLC grade) using Volta Lab
model PGP201 with a platinum working electrode, a platinum
wire auxiliary electrode and silver wire pseudo-reference elec-
trode. To control the temperature, a Haake D8-G refrigerated
bath and circulator were used to maintain the cell temperature
at 25.0 ± 0.1 C. Tetrabutylammonium hexaﬂuorophosphate
(0.1 M) was used as the supporting electrolyte.
2.1.3. General procedure for the synthesis of complexes
A solution of cis-[PdCl2(PhCN)2] (0.38 g, 1.0 mmol) in 20 cm
3
acetone was slowly added to a magnetically stirred solution of
L (1.1 mmol) in 20 cm3 acetone. The yellow precipitate was ﬁl-
tered after 24 h. The precipitate was washed successively with
acetone (3 · 5 cm3) diethyl ether (3 · 5 cm3), and dried in a
vacuum oven at 25 C.
1: Yield (2.61 g, 52%). Found: C, 42.10%; H, 3.23%; N,
9.92%. Anal. Calc. for PdC15H13N3OCl2: C, 42.03; H, 3.06;
N, 9.80. UV–Vis in acetonitrile: kmax (emax): 357 (8.83 · 104),
242 (5.24 · 104), 219 (6.90 · 104). IR (KBr, cm1): m(N‚N)
1496, m(C‚N) 1601, m(C‚O) 1668. 1H NMR (in CDCl3, d
ppm): 7.30 (2H, d, H3, H30), 7.29 (2H, t, H4, H40), 7.10 (2H,
t, H1, H10), 6.90 (1H, t, H5), 6.75 (1H, t, X = H), 6.55 (2H,
d, H2, H20), 2.50 (3H, s, COCH3).
2: Yield (3.02 g, 57%). Found: C, 43.10%; H, 3.21%; N,
9.53%. Anal. Calc. for PdC16H15N3OCl2: C, 43.42; H, 3.42;
N, 9.49. UV–Vis in acetonitrile: kmax (emax): 356 (8.09 · 104),
241 (4.69 · 104), 214 (6.24 · 104). IR (KBr, cm1): m(N‚N)
1478, m(C‚N) 1599, m(C‚O) 1664. 1H NMR (in CDCl3, d
ppm): 7.27 (2H, d, H3, H30), 6.95 (2H, d, H2, H20), 6.45
(2H, d, H1, H10), 6.2 (3H, m, H4, H40, H5), 2.59 (3H, s,
COCH3), 2.05 (3H, s, CH3).
3: Yield (3.33 g, 57%). Found: C, 41.25%; H, 3.25%; N,
8.12%. Anal. Calc. for PdC15H12N3OCl3ÆC3H6O: C, 41.49;
H, 3.48; N, 8.06. UV–Vis in acetonitrile: kmax (emax): 354
(9.01 · 104), 245 (5.38 · 104), 212 (7.02 · 104). IR (KBr, cm
1): m(N‚N) 1491, m(C‚N) 1599, m(C‚O) 1675. 1H NMR
(in CDCl3, d ppm): 7.27 (2H, d, H2, H20), 6.98 (1H, t, H5),
7.1 (2H, d, H1, H10), 7.21 (2H, d, H3, H30), 7.30 (2H, t, H4,
H40), 2.6 (3H, s, COCH3).
4: Yield (4.02 g, 60%). Found: C, 36.57%; H, 2.88%; N,
7.52%. Anal. Calc. for PdC15H12BrN3OCl2Æ0.5ÆC3H6O: C,
36.49; H, 2.82; N, 7.83. UV–Vis in acetonitrile: kmax (emax):
358 (8.92 · 104), 243 (5.32 · 104), 214 (6.98 · 104). IR (KBr,
cm1): m(N‚N) 1478, m(C‚N) 1596, m(C‚O) 1675. 1H
NMR (in CDCl3, d ppm): 6.51 (2H, d, H2, H20), (1H, t,
H5), 7.1 (2H, d, H3, H30), 7.31 (2H, t, H4, H40), 7.35 (2H, d,
H1, H10), 2.60 (3H, s, COCH3).
5: Yield (3.82 g, 63%). Found: C, 47.43%; H, 3.21%; N,
8.53%. Anal. Calc. for for PdC19H15N3OCl2: 47.62; H, 3.16;
N, 8.78. UV–Vis in acetonitrile: kmax (emax): 329 (8.80 · 104),
Palladium(II) complexes incorporating phenylazo arylmethine ancillary ligands S1505239 (5.20 · 104), 212 (6.86 · 104). IR (KBr, cm1): m(N‚N)
1504, m(C‚N) 1600, m(C‚O) 1673. 1H NMR (in CDCl3, d
ppm): 6.34 (1H, d, H(naphthyl proton)), 6.91 (1H, t, H5),
7.04 (2H, d, H(naphthyl proton)), 7.31 (3H, m, H4, H40,
H(naphthyl proton)), 7.6 (3H, m, H3, H30, H(naphthyl pro-
ton)), 7.9 (1H, d, H(naphthyl proton)), 8.1(1H, d, naphthyl
proton), 2.60 (3H, s, COCH3).
6: Yield (3.11 g, 55%). Found: C, 41.71%; H, 3.21%; N,
913%. Anal. Calc. for PdC16H15N3O2Cl2: C, 41.90; H, 3.30;
N, 9.16. UV–Vis in acetonitrile: kmax (emax): 357 (8.75 · 104),
297 (5.0 · 104), 240 (6.78 · 104). IR (KBr, cm1): m(N‚N)
1504, m(C‚N) 1618, m(C‚O) 1660. 1H NMR (in CDCl3, d
ppm): 6.62 (2H, d, H1, H10), 6.80 (2H, d, H2, H20), 6.92
(1H, t, H5), 7.03 (2H, t, H4, H40), 7.25 (2H, d, H3, H30),
3.75 (3H, s, OCH3), 2.60 (3H, s, COCH3).
2.2. Biology
2.2.1. Cell culture
Human T47D ductal breast epithelial tumor cell line was grown
in DMEM-F12 medium (Lonza, Switzerland) supplemented
with 10% fetal calf serum (FCS) (Euroclone, Italy). Murine
mammary MTLn3 adenocarcinoma cell line was cultured in
a-MEM (Gibco Laboratories, USA) supplemented with 5%
FCS. Murine RAW 264.7 leukemic monocyte macrophage cell
was cultured in RPMI-1640 (Euroclone, Italy) supplemented
with 10% FCS. Trypsin–EDTA (Lonza, Switzerland) was rou-
tinely used for subcultures. Cell growth was accomplished at
37 C in a 5% carbon dioxide atmosphere.
2.2.2. In vitro cytotoxicity MTT test
Cytotoxicity of the various palladium complexes on T47D,
MTLn3 and RAW 264.7 cells was evaluated by means of
MTT (tetrazolium salt reduction) test (Mosmann, 1983;
Fotakis and Timbrell, 2006). Brieﬂy, 5 · 104 viable cells
(counted using the Trypan Blue Exclusion Test) were added
to each well of a 96-well tissue culture plate containing growth
media supplemented with FCS (Freshney, 2000). Cells were
kept in a humiﬁed 5% CO2 incubator at 37 C for 24 h. Four
complexes (2–5) were tested and for each complex six concen-
trations were prepared in growth media: 0.1, 0.5, 2.5, 5, 25, and
50 lg/ml. The complexes were solubilized in 10% DMSO,
while complex L5 was solubilized in 50% DMSO. The next
morning, the different concentrations were added, and the cells
were incubated for 24 h. Freshly prepared MTT salt (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
(5 mg/ml) was added to each well to give a ﬁnal concentration
of 0.5 lg/ll. The plates were incubated for 4 h and the forma-N
N
N
O
X
Pd(NCPh)2C
X H Me Cl 
L L1 L2 L3 
Complex 1 2 3 
Scheme 1 The chemical structures of lition of formazan crystals was checked using an inverted micro-
scope. Equal volume of 1:1 (200 ll) of mix of DMSO and
isopropanol was added to each well and incubated for 30–
45 min. the inhibition of cell growth induced by the various
complexes was detected by measuring the absorbance of each
well at 570 nm using a Statfax microplate reader. For compar-
ison purposes, the cytotoxicity of cisplatin was evaluated under
the same experimental conditions.
2.2.3. Clonogenic assay
2 · 105 cells (counted using a hemocytometer) were seeded in
tissue culture dishes containing growth media supplemented
with FCS. Cells were kept in a humiﬁed 5% CO2 incubator
at 37 C for 24 h. Afterwards, the medium was replaced and
the cells were incubated for 3 h in the presence of an increasing
concentration of tested complexes (0.1, 0.5, 2.5, 5, 25, and
50 lg/ml). Aliquots of 200 cells were seeded in growth medium
and incubated for 12 days. The colonies were then stained and
counted, discarding colonies with less than 50 cells. The surviv-
ing fraction (SF) was calculated according to Alverdi et al.,
2004 and Franken et al., 2006.
3. Results and discussion
3.1. Chemistry
The ligands (L1–L6) {L = C6H5N‚NC(COCH3)‚NC6H4X)
( Scheme 1) were synthesized by condensation of the corre-
sponding hydrazonyl chloride with aniline derivatives in good
yields (Al-Noaimi et al., 2008). These ligands are bidentate
chelaters where the active function is the azoimine group
(N‚N–C‚N). The basicity of nitrogen as a donor atom in
the ligands was controlled by varying the substituents (X). It
is well known that the electron withdrawing substituent dimin-
ishes Lewis basicity of the nitrogen donor (Cotton et al., 1995).
The reaction of cis-[PdCl2(PhCN)2] with the ligands (L1–
L6) in acetone at room temperature yielded the corresponding
cis-[PdCl2L] complexes as a yellow solid. Complexes 1–6 have
been characterized by elemental analysis, infrared spectros-
copy, 1H-NMR spectroscopy, as well as, and electrochemical
(CV) techniques.
Elemental analyses of the complexes (1–6) showed that the
metal to the azoimine ligand ratio in the dichloro complexes is
1:1. This indicates that the complexes are in the monomer
form, the palladium ion is tetra coordinated surrounded by
one azoimine ligand and two chloride ligands. The aromatic
region in the 1H-NMR spectra of the complexes (1–6) consists
of several coupled multiplets due to aromatic protons of theN
N
N
O
X
Pd
ClCl
l2
123     4
5
Br Naphtyl Ome 
L4 L5 L6 
4 5 6 
gands (L1–L6) and complexes (1–6).
Table 1 Cyclic voltammetry and electronic spectroscopy data
of cis-[PdCl2L], complexes (1–6).
a
Complex kmax (nm)
b L(0/) (V)c
1 357, 242, 219 0.20
2 356, 241, 214 0.21
3 354, 245, 212 0.13
4 358, 243, 214 0.10
5 329, 239, 212 0.21
6 361, 240, 215 0.15
a Solvent: acetonitrile; supporting electrolyte: Bu4NPF6 (0.1 M);
scan rate: 0.1 V s; Pt-disk working electrode, Pt-wire auxiliary
electrode, reference electrode Ag at 25 C.
b Solvent: acetonitrile.
c Reduction potential.
Table 2 Cytotoxicity data (IC50, lM) of palladium complexes
against human T47D, murine MTLn3 and RAW tumor cell
lines.
Complex T47D MTLn3 RAW
Cisplatin 71.8 38.7 48.3
2 299.3 321.5 249.1
3 269.3 351.9 224.0
4 40.7 81.7 91.1
5 57.5 55.4 102.5
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complexes show bands in the range of 1660–1712 cm1 assign-
able to C‚O stretching frequency of the acetyl group. The in-
tense bands in the ranges of 1560–1590 and 1430–1500 cm1Voltage (vs. A
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Figure 1 Cyclic voltammogram for 1 in acetonitrile
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Figure 2 Electronic spectra of L1were assigned to the C‚N and N‚N stretching bands of azo-
imine ligands, respectively.
Electrochemical measurements in the presence of tetrabu-
tylammonium hexaﬂuoro-phosphate as supporting electrolyte
were carried out using a Pt-disk working electrode in MeCN
solution. The results are given in Table 1, and a representative
voltammogram is shown in Fig. 1. cis-[PdCl2L] (1–6) exhibit
one irreversible reduction responses in the potential rangeg wire electrode)
0.2 0.0 0.2 0.4
0.1 M TBAH at 25 C with scan rate of 0.1 V/s.
gth (nm)
50 400 450 500
and complex 1 in acetonitrile.
Figure 3 Survival curves of T47D (a), MTLn3 (b) and RAW (c) cells after treatment with palladium(II) complexes and cisplatin.
Palladium(II) complexes incorporating phenylazo arylmethine ancillary ligands S1507(0.1 to 0.20) V. We suggest that this couple is due to reduc-
tion of the azoimine ligand L(/0). These complexes are easyto reduce due to the fact that azoimine is a good p-acceptor
ligand. However, cis-[PdCl2L] (1–6) does not exhibit redox
S1508 M. Al-Noaimi et al.response in the positive side because Pd(II) is redox-inactive.
Among the six complexes, the potential of the L(0/) couple
is slightly affected by variations in the substituent Y on the
azoimine ligand, being shifted to more positive potentials upon
replacing the donating group with the more withdrawing
groups.
The absorption spectra were recorded in a MeCN solution
in the wavelength range 250–800 nm. The bands in the UV–
visible spectra of complexes 1–6 were assigned upon compari-
son with spectrum of the free ligands (L1–L6) (Fig. 2). For the
free ligands, the absorption between 200–300 nm and 300–400
bands for L1 (as representative example) are assigned to
nﬁ p* and pﬁ p* transitions, respectively. These bands are
shifted to lower energy upon complexation. The structured
absorption bands between 250–350 and 350–450 nm for com-
plex 1 (as representative example) are assigned to nﬁ p* and
pﬁ p* transitions, respectively. A tail extending into 500 nm
may arise from metal-orbital to ligand-orbital charge transi-
tion: dp(Pd10)ﬁp*(ligand) state of the azoimine.
3.2. Biological investigations
The cytotoxic activities of selected palladium(II) complexes
incorporating ligands with electron withdrawing (X = Cl (3)
and Br (4)) and electron releasing groups (X = CH3 (2) and
naphthyl (5)) have been evaluated against human T47D breast
tumor cell line, murine mammary MTLn3 adenocarcinoma
cell line and murine RAW 264.7 leukemia cell line. The results
are shown in Table 2 in terms of IC50 values (the concentration
needed to inhibit 50% of the cellular proliferation). For com-
parison purposes, the cytotoxicity of cisplatin, a standard anti-
tumor drug, was tested under the same conditions. As listed in
Table 2, the complexes 4 and 5 exerted cytotoxic effects against
the three cell lines, T47D, MTLn3 and RAW 264.7. Moreover,
they have selectivity against tested tumor cell lines.
Palladium(II) complex with X = Br (4) showed the highest
cytotoxic activity against human T47D breast tumor cell line
compared with other complexes (2, 3, and 5). It also exhibited
a higher cytotoxicity (IC50 = 40.7 lM) than cisplatin (IC50 =
71.8 lM) (Table 2). It can be also seen that the complex with
X = naphthyl (5) was more active (IC50 = 57.5 lM) than cis-
platin against the same tumor cell line (Table 2). Complex 5
which contains azoimine ligand with naphthyl group demon-
strated a higher cytotoxicity (IC50 = 55.4 lM) than the corre-
sponding complexes 2 (321.5 lM), 3 (351.9 lM) and 4
(81.7 lM) against murine mammary MTLn3 adenocarcinoma
cell line, but comparable with that of cisplatin (IC50 =
38.7 lM). Similar trend was also observed in the cytotoxic
properties of the complexes against murine RAW 264.7 leuke-
mia cell line, but the complexes were less active than cisplatin.
In general, the more the electronegativity of the substituent
(X) on the azoimine ligand the more it enhances the cytotoxic-
ity of the complexes against the above cell lines (BrP naph-
thyl > ClP CH3). Based on the cytotoxic activity results
above, both electronic properties and bulkiness of the substitu-
ent have a noticeable inﬂuence on the activity of the palla-
dium(II) complexes. The antiproliferative activity of the new
complexes was also evaluated by studying the effect on clonal
growth capacity of cells (Fig. 3a–c). The obtained data suggest
that all palladium derivatives show a signiﬁcant activity similar
to that of the reference drug (cisplatin).4. Conclusions
Azoimine palladium(II) complexes of the general type cis-
[PdCl2L] (1–6) {L = PhN‚NC(COMe)‚NC6H4X, where
X = H (L1), CH3 (L2), Cl (L3), Br (L4), naphthyl (L5) and
OMe (L6)} have been synthesized and characterized by ele-
mental analysis, spectroscopic and electrochemical (CV) tech-
niques. Cyclic voltammetric studies show one irreversible
responses negative to silver wire electrode which is assigned
to L(/0) couple. These complexes are easy to reduce due to
the fact that azoimine is a good p- acceptor ligand. However,
cis-[PdCl2L] (1–6) does not exhibit redox response in the posi-
tive side because PdII is redox-inactive. The in vitro cytotoxic
potential (IC50) studies against T47D, MTLn3 and RAW tu-
mor cell lines show a satisfactory inhibitory effect on cells com-
parable to that of cisplatin.Acknowledgement
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